GERD in Children With Cystic Fibrosis

This study is looking at children with cystic fibrosis (CF) to understand how common gastroesophageal reflux disease (GERD) symptoms are. Researchers will use a survey called the Gastroesophageal Symptom Assessment Scale (GSAS) to measure these symptoms. For some children already taking GERD medicine, this study will look at what happens to their symptoms if they stop taking that medicine. To join, children must be between 2 and 18 years old with a confirmed CF diagnosis. Children with severe GERD or a very high GSAS score cannot participate. The study aims to enroll 20 children, but its current status is unclear.

Study design
This is an interventional study planning to enroll 20 participants. It will look at the impact of stopping GERD therapy.
What's involved
Participants will have their GERD therapy discontinued at the time of enrollment. Symptoms will be assessed at baseline and 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06617013

GERD in Children With Cystic Fibrosis

Recruiting
NAAges 2–18InterventionalTreatment
Duke University
~20 participants
Updated 2025-12-19 on ClinicalTrials.gov
What's tested:Discontinuation of GERD therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in the mean GSAS score (only if GERD medication discontinued)
Measured over baseline and 12 weeks
+2 more outcomes measured
GERD in Children
Cystic Fibrosis in Children
1 sites across 1 states
North Carolina1
  • Shatha Yousef · PRINCIPAL_INVESTIGATOR · Duke University Hospital

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
Signed consent

Exclusion

Declining to participate in the study or sign consent
History of severe GERD per gastroenterology diagnosis and documentation
GSAS score \>80
  • Change from baseline in the mean GSAS score (only if GERD medication discontinued)baseline and 12 weeks

    The Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) is a 15-item tool validated in children in assessing gastroesophageal reflux disease-related symptoms. The GSAS ranges from 0 to 490, with a higher score representing worse GERD symptoms, and a score ≥ 15 reflects significant GERD symptoms.

  • Mean GSAS score in children with CF on GERD therapyBaseline

    GSAS ranges from 0 to 490, with a higher score representing worse GERD symptoms, and a score ≥ 15 reflects significant GERD symptoms. A value of 80 will be used as a maximum cut-off for mild symptoms as this was 2 SD from the mean GSAS for children without baseline GERD.

  • Mean GSAS score in children with CF not on GERD therapyBaseline

    GSAS ranges from 0 to 490, with a higher score representing worse GERD symptoms, and a score ≥ 15 reflects significant GERD symptoms. A value of 80 will be used as a maximum cut-off for mild symptoms as this was 2 SD from the mean GSAS for children without baseline GERD.